We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Pfizer's Vfend as a treatment for deep-tissue skin infections,
as well as infections in the abdomen, kidney, bladder wall and wounds.
The FDA has granted marketing approval for Clolar, a drug manufactured by Genzyme
that serves as a leukemia treatment for children with refractory or relapsed
acute lymphoblastic leukemia (ALL).
Elan has been granted FDA approval for Prialt for the management of severe chronic
pain in patients who are intolerant of traditional pain medications, such at
IT morphine or systemic analgesics.
A vaccine based on a genetically modified strain of herpes simplex virus 2
-- the type usually responsible for genital infections -- rapidly
induces an immune response in mice and guinea pigs, researchers report.
Threshold Pharmaceuticals has initiated patient enrollment for a Phase I/II
clinical trial evaluating the dosing, safety and activity of Glufosfamide
in combination with gemcitabine for treating advanced solid malignancies or
as a first line treatment for pancreatic cancer.
AXONYX has completed the last six-month patient treatment period in its Phase
III double-blind placebo-controlled clinical trial with Phenserine for Alzheimer's
disease (AD).
The Medicines Company has announced successful completion of the EVOLUTION-On
Phase III clinical trial of Angiomax, the second of two safety trials of the
Angiomax Phase III cardiac surgery program.